The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

IU study: Vaccine protects most cancer patients from COVID-19, but risk remains higher for patients with blood cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman
ClinicalTrials & Tribulations

A simple intervention could help address overlooked pain among older adults with cancer in rural America

A recent article in JAMA Network Open published by myself and my research collaborators—Jill Harrison at Brown University, Sarah Yarborough at Fred Hutch, and Tammy Stokes at Maury Regional Medical Center—examined the potential for a brief communication-based intervention to help older adults with cancer who live in rural settings better manage their pain. 
By Megan J. Shen
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account